Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

4(50.0%)

Phase 1

2(25.0%)

Phase 3

1(12.5%)

Early Phase 1

1(12.5%)

8Total

Phase 2(4)

Phase 1(2)

Phase 3(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT01796795Phase 2Suspended

Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients

Role: lead

NCT01796821Phase 2Completed

Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs)

Role: lead

NCT02559934Phase 1Completed

Multiple-dose Pharmacokinetic Study of Solamargine in Patients With Actinic Keratosis

Role: lead

NCT01516515Phase 2Completed

Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis

Role: lead

NCT01493921Phase 3Completed

Efficacy Study & Safety Evaluation of SR-T100 Gel in Actinic Keratosis Treatment

Role: lead

NCT02029066Phase 1Completed

Pharmacokinetic Study of Solamargine in Patients With Actinic Keratosis

Role: lead

NCT01676792Early Phase 1Completed

SR-T100 Gel Efficacy & Safety Study for Vulva Pre-cancerous Lesions & Cutaneous Condyloma

Role: collaborator

NCT02085395Phase 2Completed

Clinical Study Assessment of SR-T100 Topical Gel Against Actinic Keratosis

Role: lead

All 8 trials loaded